Home / Publications / New insight into the antiaggregant activity of furoxans

New insight into the antiaggregant activity of furoxans

Nadezhda Evgenievna Ustyuzhanina 1
Nadezhda Evgenievna Ustyuzhanina
Marina Leonidovna Gening 1
Marina Leonidovna Gening
Nikolay Eduardovich Nifantiev 1
Nikolay Eduardovich Nifantiev
Nina Nikolaevna Makhova 1
Nina Nikolaevna Makhova
Published 2016-10-27
CommunicationVolume 26, Issue 6, 513-515
30
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Ustyuzhanina N. E. et al. New insight into the antiaggregant activity of furoxans // Mendeleev Communications. 2016. Vol. 26. No. 6. pp. 513-515.
GOST all authors (up to 50) Copy
Ustyuzhanina N. E., Fershtat L. L., Gening M. L., Nifantiev N. E., Makhova N. N. New insight into the antiaggregant activity of furoxans // Mendeleev Communications. 2016. Vol. 26. No. 6. pp. 513-515.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2016.11.018
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2016.11.018
TI - New insight into the antiaggregant activity of furoxans
T2 - Mendeleev Communications
AU - Ustyuzhanina, Nadezhda Evgenievna
AU - Fershtat, Leonid Leonidovich
AU - Gening, Marina Leonidovna
AU - Nifantiev, Nikolay Eduardovich
AU - Makhova, Nina Nikolaevna
PY - 2016
DA - 2016/10/27
PB - Mendeleev Communications
SP - 513-515
IS - 6
VL - 26
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2016_Ustyuzhanina,
author = {Nadezhda Evgenievna Ustyuzhanina and Leonid Leonidovich Fershtat and Marina Leonidovna Gening and Nikolay Eduardovich Nifantiev and Nina Nikolaevna Makhova},
title = {New insight into the antiaggregant activity of furoxans},
journal = {Mendeleev Communications},
year = {2016},
volume = {26},
publisher = {Mendeleev Communications},
month = {Oct},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2016.11.018},
number = {6},
pages = {513--515},
doi = {10.1016/j.mencom.2016.11.018}
}
MLA
Cite this
MLA Copy
Ustyuzhanina, Nadezhda Evgenievna, et al. “New insight into the antiaggregant activity of furoxans.” Mendeleev Communications, vol. 26, no. 6, Oct. 2016, pp. 513-515. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2016.11.018.

Abstract

The measurement of the antiaggregant properties of 3-cyano-4-phenylfuroxan and 3-nitro-4-phenylfuroxan has demonstrated that these compounds effectively inhibit platelet agglutination induced by adenosine diphosphate and adrenaline but not ristocetin. When collagen was used as an inducer, only a slight delay of aggregate formation was observed. Therefore, these furoxan derivatives could be considered as a basis for the development of next generation agents with improved antiaggregant activity.

References

1.
Ananikov V.P., Galkin K.I., Egorov M.P., Sakharov A.M., Zlotin S.G., Redina E.A., Isaeva V.I., Kustov L.M., Gening M.L., Nifantiev N.E.
Mendeleev Communications, 2016
2.
Zlotin S.G., Churakov A.M., Luk’yanov O.A., Makhova N.N., Sukhorukov A.Y., Tartakovsky V.A.
Mendeleev Communications, 2015
4.
Pharmacological Properties of Furoxans and Benzofuroxans: Recent Developments
Cerecetto H., Porcal W.
Mini-Reviews in Medicinal Chemistry, 2005
5.
NO donors: Focus on furoxan derivatives
Gasco A., Fruttero R., Sorba G., Di Stilo A., Calvino R.
Pure and Applied Chemistry, 2004
6.
Furoxans (1,2,5-Oxadiazole-N-Oxides) as Novel NO Mimetic Neuroprotective and Procognitive Agents
Schiefer I.T., VandeVrede L., Fa’ M., Arancio O., Thatcher G.R.
Journal of Medicinal Chemistry, 2012
8.
10.1016/j.mencom.2016.11.018_sbref0020b
Aguirre
Pharmazie, 2006
10.
Oxadiazole 2-oxides are toxic to the human hookworm, Ancylostoma ceylanicum, however glutathione reductase is not the primary target
Treger R.S., Cook A., Rai G., Maloney D.J., Simeonov A., Jadhav A., Thomas C.J., Williams D.L., Cappello M., Vermeire J.J.
International Journal for Parasitology: Drugs and Drug Resistance, 2012
11.
Design, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds to Treat Sickle Cell Disease Symptoms. Part II: Furoxan Derivatives
Dos Santos J.L., Lanaro C., Chelucci R.C., Gambero S., Bosquesi P.L., Reis J.S., Lima L.M., Cerecetto H., González M., Costa F.F., Chung M.C.
Journal of Medicinal Chemistry, 2012
12.
Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents
Rai G., Thomas C.J., Leister W., Maloney D.J.
Tetrahedron Letters, 2009
13.
Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans
Lazzarato L., Cena C., Rolando B., Marini E., Lolli M.L., Guglielmo S., Guaita E., Morini G., Coruzzi G., Fruttero R., Gasco A.
Bioorganic and Medicinal Chemistry, 2011
14.
Furoxan nitric oxide donor coupled chrysin derivatives: Synthesis and vasculoprotection
Zou X., Peng S., Hu C., Tan L., Deng H., Li Y.
Bioorganic and Medicinal Chemistry Letters, 2011
15.
Unsymmetrically substituted furoxans. Part 19. Methyl and phenylfuroxansulfonic acids and related sulfonamides
Chegaev K., Rolando B., Guglielmo S., Fruttero R., Gasco A.
Journal of Heterocyclic Chemistry, 2009
16.
Studies of the potential genotoxic effects of furoxans: The case of CAS 1609 and of the water-soluble analogue of CHF 2363
Balbo S., Lazzarato L., Di Stilo A., Fruttero R., Lombaert N., Kirsch-Volders M.
Toxicology Letters, 2008
17.
Nitric Oxide Donor β2-Agonists:  Furoxan Derivatives Containing the Fenoterol Moiety and Related Furazans
Buonsanti M.F., Bertinaria M., Di Stilo A., Cena C., Fruttero R., Gasco A.
Journal of Medicinal Chemistry, 2007
18.
Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets
Turnbull C.M., Cena C., Fruttero R., Gasco A., Rossi A.G., Megson I.L.
British Journal of Pharmacology, 2006
19.
Role of carbon monoxide and nitric oxide in adult rat hepatocytes proliferating in vitro: Effects of CAS 1609
Krause P., Wätzig E., Acil H., König S., Unthan-Fechner K., Tsikas D., Probst I.
Nitric Oxide - Biology and Chemistry, 2010
21.
Vasorelaxant and antiplatelet activity of 4,7-dimethyl-1,2,5-oxadiazolo[3,4-d]pyridazine 1,5,6-trioxide: Role of soluble guanylate cyclase, nitric oxide and thiols
Kots A.Y., Grafov M.A., Khropov Y.V., Betin V.L., Belushkina N.N., Busygina O.G., Yazykova M.Y., Ovchinnikov I.V., Kulikov A.S., Makhova N.N., Medvedeva N.A., Bulargina T.V., Severina I.S.
British Journal of Pharmacology, 2000
22.
No-Mimetic Furoxans: Arylsulphonylfuroxans and Related Compounds
Ferioli R., Fazzini A., Folco G.C., Fruttero R., Calvino R., Gasco A., Bongrani S., Civelli M.
Pharmacological Research, 1993
23.
A new class of furoxan derivatives as NO donors: mechanism of action and biological activity
Ferioli R., Folco G.C., Ferretti C., Gasco A.M., Medana C., Fruttero R., Civelli M., Gasco A.
British Journal of Pharmacology, 1995
24.
An efficient access to (1H-tetrazol-5-yl)furoxan ammonium salts via a two-step dehydration/[3+2]-cycloaddition strategy
Fershtat L.L., Epishina M.A., Kulikov A.S., Ovchinnikov I.V., Ananyev I.V., Makhova N.N.
Tetrahedron, 2015
25.
Nitrosation of salts of 1-hydroxyimino-2,2-dinitro-1-R-ethanes, a novel method for the preparation of isomeric 3(4)-nitro-4(3)-R-furoxans
Ovchinnikov I.V., Finogenov A.O., Epishina M.A., Kulikov A.S., Strelenko Y.A., Makhova N.N.
Russian Chemical Bulletin, 2009
26.
ADP-lnduced Platelet Activation
Puri R.N., Colman R.W., Liberman M.A.
Critical Reviews in Biochemistry and Molecular Biology, 1997
27.
Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease
Ueno M., Kodali M., Tello-Montoliu A., Angiolillo D.J.
Journal of Atherosclerosis and Thrombosis, 2011